117 related articles for article (PubMed ID: 23131782)
1. A potential therapeutic application of SET/I2PP2A inhibitor OP449 for canine T-cell lymphoma.
Fujiwara N; Kawasaki H; Yabe R; Christensen DJ; Vitek MP; Mizuno T; Sato K; Ohama T
J Vet Med Sci; 2013; 75(3):349-54. PubMed ID: 23131782
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effects of perphenazine on canine lymphoma.
Tsuji S; Yabe R; Usui T; Mizuno T; Ohama T; Sato K
J Vet Med Sci; 2016 Sep; 78(8):1293-8. PubMed ID: 27150024
[TBL] [Abstract][Full Text] [Related]
4. Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia.
Richard NP; Pippa R; Cleary MM; Puri A; Tibbitts D; Mahmood S; Christensen DJ; Jeng S; McWeeney S; Look AT; Chang BH; Tyner JW; Vitek MP; Odero MD; Sears R; Agarwal A
Oncotarget; 2016 Dec; 7(51):84214-84227. PubMed ID: 27705940
[TBL] [Abstract][Full Text] [Related]
5. Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis.
Enjoji S; Yabe R; Tsuji S; Yoshimura K; Kawasaki H; Sakurai M; Sakai Y; Takenouchi H; Yoshino S; Hazama S; Nagano H; Oshima H; Oshima M; Vitek MP; Matsuura T; Hippo Y; Usui T; Ohama T; Sato K
Mol Cancer Res; 2018 Mar; 16(3):554-563. PubMed ID: 29330298
[TBL] [Abstract][Full Text] [Related]
6. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
7. Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma.
Goto RN; Sobral LM; Stringhetta-Padovani K; Garcia CB; da Silva G; Vitek MP; Leopoldino AM
Eur J Pharmacol; 2020 Sep; 882():173268. PubMed ID: 32569675
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SET/I2PP2A isoforms in dogs.
Yabe R; Fujiwara N; Mizuno T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2014 Sep; 76(9):1235-40. PubMed ID: 24897959
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
11. SETting OP449 into the PP2A-activating drug family.
Neviani P; Perrotti D
Clin Cancer Res; 2014 Apr; 20(8):2026-8. PubMed ID: 24634375
[TBL] [Abstract][Full Text] [Related]
12. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
[TBL] [Abstract][Full Text] [Related]
13. Ceramide in the prostate.
Dent P
Cancer Biol Ther; 2013 Oct; 14(10):881-2. PubMed ID: 24025252
[TBL] [Abstract][Full Text] [Related]
14. Treatment of T cell lymphoma in dogs.
Moore AS
Vet Rec; 2016 Sep; 179(11):277. PubMed ID: 27634860
[TBL] [Abstract][Full Text] [Related]
15. Bupivacaine induces apoptosis through caspase-dependent and -independent pathways in canine mammary tumor cells.
Chiu YS; Cheng YH; Lin SW; Chang TS; Liou CJ; Lai YS
Res Vet Sci; 2015 Jun; 100():232-8. PubMed ID: 25843897
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of microRNA-199b predicts unfavorable prognosis and emerges as a novel therapeutic target which contributes to PP2A inhibition in metastatic colorectal cancer.
Cristóbal I; Caramés C; Rincón R; Manso R; Madoz-Gúrpide J; Torrejón B; González-Alonso P; Rojo F; García-Foncillas J
Oncotarget; 2017 Jun; 8(25):40169-40180. PubMed ID: 27517624
[TBL] [Abstract][Full Text] [Related]
17. Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013).
Goodman IH; Moore AS; Frimberger AE
Vet J; 2016 May; 211():39-44. PubMed ID: 27017053
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the cytotoxic effect of flavopiridol in canine lymphoma cell lines.
Ema Y; Igase M; Takeda Y; Yanase T; Umeki S; Hiraoka H; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():95-106. PubMed ID: 25623777
[TBL] [Abstract][Full Text] [Related]
19. PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.
Galiger C; Dahlhaus M; Vitek MP; Debatin KM; Beltinger C
Front Oncol; 2022; 12():744984. PubMed ID: 35814385
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma.
Lucroy MD; Phillips BS; Kraegel SA; Simonson ER; Madewell BR
J Vet Intern Med; 1998; 12(5):325-9. PubMed ID: 9773407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
